category,datetime,headline,id,image,related,source,summary,url
company,1768561567,Should ResMed's (RMD) Earnings Beat and Margin Gains Require Action From Investors?,138151076,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,RMD,Yahoo,"In its recent past quarterly update, ResMed reported US$1.34 billion in revenue, growing around 9% year on year, with earnings per share ahead of analyst expectations while revenue aligned with forecasts. This performance, alongside multi‑year gains in earnings per share and free cash flow margins from its cloud‑connected respiratory devices, highlights how ResMed has been improving profitability and financial flexibility as it expands globally. We’ll now examine how ResMed’s earnings beat...",https://finnhub.io/api/news?id=31b54d3b1bf6db83c52a82b90f29f4129bf34f4aa5d91a46e8bce25e7365510a
company,1768547267,A Look At ResMed (RMD) Valuation After Earnings Beat And Strong Start To Fiscal 2026,138148767,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,RMD,Yahoo,"ResMed (RMD) shares recently moved after an earnings report that showed a beat on EPS estimates while revenue matched expectations. Management described fiscal 2026 as off to a strong start. See our latest analysis for ResMed. The earnings beat appears to have supported a recent shift in sentiment, with ResMed posting a 5.4% 1 month share price return but a 2.8% 3 month share price decline. The 1 year total shareholder return sits at 10.9%, suggesting momentum has been rebuilding after a...",https://finnhub.io/api/news?id=cfd117c818fac4bfb697cf387a1bd31a919c0d5caf540d822856d64e343bfd4c
company,1768543839,Is It Time To Reassess ResMed (RMD) After Recent Sleep Care Tailwinds?,138148768,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,RMD,Yahoo,"If you are wondering whether ResMed's current share price still offers value, this article walks through what the numbers are actually saying about the stock today. ResMed recently closed at US$260.70, with reported returns of 3.9% over 7 days, 5.4% over 30 days, 6.5% year to date, 10.9% over 1 year, 16.9% over 3 years, and 25.3% over 5 years. This gives useful context before looking at valuation. Recent headlines around ResMed have focused on ongoing interest in sleep and respiratory care...",https://finnhub.io/api/news?id=cfa63f236479a0bd6baf015a4109193daaaa903d44f680e1cdae08c932d99de2
